Charles River Laboratories Intl. Inc (NYSE:CRL) Receives Consensus Recommendation of “Buy” from Analysts

Charles River Laboratories Intl. Inc (NYSE:CRL) has earned a consensus recommendation of “Buy” from the nineteen analysts that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $178.83.

A number of brokerages recently issued reports on CRL. JPMorgan Chase & Co. boosted their target price on shares of Charles River Laboratories Intl. from $160.00 to $180.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Deutsche Bank dropped their target price on shares of Charles River Laboratories Intl. from $190.00 to $174.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Morgan Stanley boosted their target price on shares of Charles River Laboratories Intl. from $152.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Zacks Investment Research lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. Finally, SunTrust Banks boosted their price target on shares of Charles River Laboratories Intl. from $130.00 to $194.00 and gave the company a “buy” rating in a report on Friday, May 8th.

In related news, VP Birgit Girshick sold 780 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $165.74, for a total transaction of $129,277.20. Following the transaction, the vice president now owns 21,837 shares in the company, valued at approximately $3,619,264.38. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director George Massaro sold 941 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $173.40, for a total transaction of $163,169.40. Following the transaction, the director now owns 12,222 shares in the company, valued at approximately $2,119,294.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,697 shares of company stock worth $3,744,212. 1.90% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of CRL. SeaBridge Investment Advisors LLC acquired a new position in Charles River Laboratories Intl. during the 2nd quarter worth about $35,000. Legacy Wealth Planning LLC acquired a new position in Charles River Laboratories Intl. during the 1st quarter worth about $36,000. Patriot Financial Group Insurance Agency LLC lifted its position in Charles River Laboratories Intl. by 15,300.0% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 308 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 306 shares during the period. Synovus Financial Corp acquired a new position in Charles River Laboratories Intl. during the 1st quarter valued at about $39,000. Finally, Cullen Frost Bankers Inc. lifted its position in Charles River Laboratories Intl. by 46.2% during the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 103 shares during the period. Institutional investors and hedge funds own 93.25% of the company’s stock.

Shares of Charles River Laboratories Intl. stock opened at $198.99 on Friday. The firm has a fifty day simple moving average of $183.54 and a 200-day simple moving average of $160.27. The company has a current ratio of 1.75, a quick ratio of 1.51 and a debt-to-equity ratio of 1.49. Charles River Laboratories Intl. has a 1-year low of $95.58 and a 1-year high of $203.26. The stock has a market capitalization of $9.85 billion, a price-to-earnings ratio of 40.04, a PEG ratio of 2.09 and a beta of 1.19.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Thursday, May 7th. The medical research company reported $1.84 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.46 by $0.38. Charles River Laboratories Intl. had a net margin of 9.09% and a return on equity of 22.69%. The business had revenue of $707.06 million for the quarter, compared to analyst estimates of $692.11 million. During the same quarter in the previous year, the firm posted $1.40 earnings per share. Charles River Laboratories Intl.’s revenue was up 17.0% compared to the same quarter last year. As a group, research analysts predict that Charles River Laboratories Intl. will post 6.88 earnings per share for the current year.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: Shanghai Stock Exchange Composite Index

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply